Although PSA is regarded as the best biochemical marker for PCa [4], an important limitation regarding its use in cancer detection is the considerable overlap of patients with PCa and those with benign prostate hyperplasia (BPH), specifically in the serum PSA range 4.0–10.0 ng/mL [4]. This evidence concerns the gene KLK3 and posterior cortical atrophy.